Terms: = Colorectal cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Treatment
1103 results:
1. Exploring the Key Signaling Pathways and ncRNAs in colorectal cancer.
Lee YJ; Kim WR; Park EG; Lee DH; Kim JM; Shin HJ; Jeong HS; Roh HY; Kim HS
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674135
[TBL] [Abstract] [Full Text] [Related]
2. Clinical impact of panel gene sequencing on therapy of advanced cancers of the digestive system: a retrospective, single center study.
Dreikhausen L; Klupsch A; Wiest I; Xiao Q; Schulte N; Betge J; Boch T; Brochhausen C; Gaiser T; Hofheinz RD; Ebert M; Zhan T
BMC Cancer; 2024 Apr; 24(1):526. PubMed ID: 38664720
[TBL] [Abstract] [Full Text] [Related]
3. pi3k/Akt/mTOR Signaling Pathway as a Target for colorectal cancer treatment.
Leiphrakpam PD; Are C
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542151
[TBL] [Abstract] [Full Text] [Related]
4. Current landscape of preoperative neoadjuvant therapies for initial resectable colorectal cancer liver metastasis.
Cheng XF; Zhao F; Chen D; Liu FL
World J Gastroenterol; 2024 Feb; 30(7):663-672. PubMed ID: 38515943
[TBL] [Abstract] [Full Text] [Related]
5. Inhibition of pi3k/AKT signaling using BKM120 reduced the proliferation and migration potentials of colorectal cancer cells and enhanced cisplatin-induced cytotoxicity.
Khameneh SC; Sari S; Razi S; Yousefi AM; Bashash D
Mol Biol Rep; 2024 Mar; 51(1):420. PubMed ID: 38483663
[TBL] [Abstract] [Full Text] [Related]
6. Inhibition of Multifunctional Protein p32/C1QBP Promotes Cytostatic Effects in Colon cancer Cells by Altering Mitogenic Signaling Pathways and Promoting Mitochondrial Damage.
Egusquiza-Alvarez CA; Moreno-Londoño AP; Alvarado-Ortiz E; Ramos-Godínez MDP; Sarabia-Sánchez MA; Castañeda-Patlán MC; Robles-Flores M
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473963
[TBL] [Abstract] [Full Text] [Related]
7. Role of deubiquitinase JOSD2 in the pathogenesis of esophageal squamous cell carcinoma.
Wang WP; Shi D; Yun D; Hu J; Wang JF; Liu J; Yang YP; Li MR; Wang JF; Kong DL
World J Gastroenterol; 2024 Feb; 30(6):565-578. PubMed ID: 38463028
[TBL] [Abstract] [Full Text] [Related]
8. Myotubularin-related-protein-7 inhibits mutant (G12V) K-RAS by direct interaction.
Weidner P; Saar D; Söhn M; Schroeder T; Yu Y; Zöllner FG; Ponelies N; Zhou X; Zwicky A; Rohrbacher FN; Pattabiraman VR; Tanriver M; Bauer A; Ahmed H; Ametamey SM; Riffel P; Seger R; Bode JW; Wade RC; Ebert MPA; Kragelund BB; Burgermeister E
Cancer Lett; 2024 Apr; 588():216783. PubMed ID: 38462034
[TBL] [Abstract] [Full Text] [Related]
9. Clonal origin and genomic diversity in Lynch syndrome-associated endometrial cancer with multiple synchronous tumors: Identification of the pathogenicity of MLH1 p.L582H.
Takahashi K; Yachida N; Tamura R; Adachi S; Kondo S; Abé T; Umezu H; Nyuzuki H; Okuda S; Nakaoka H; Yoshihara K
Genes Chromosomes Cancer; 2024 Mar; 63(3):e23231. PubMed ID: 38459936
[TBL] [Abstract] [Full Text] [Related]
10. Understanding the molecular mechanism responsible for developing therapeutic radiation-induced radioresistance of rectal cancer and improving the clinical outcomes of radiotherapy - A review.
Jain SM; Nagainallur Ravichandran S; Murali Kumar M; Banerjee A; Sun-Zhang A; Zhang H; Pathak R; Sun XF; Pathak S
Cancer Biol Ther; 2024 Dec; 25(1):2317999. PubMed ID: 38445632
[TBL] [Abstract] [Full Text] [Related]
11. Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer.
Liu H; Zhou D; Liu D; Xu X; Zhang K; Hu R; Xiong P; Wang C; Zeng X; Wang L; Zhang S
Cell Death Dis; 2024 Mar; 15(3):187. PubMed ID: 38443386
[TBL] [Abstract] [Full Text] [Related]
12. Broccoli extracellular vesicles enhance the therapeutic effects and restore the chemosensitivity of 5-fluorouracil on colon cancer.
Cao Y; Hou L; Li M; Zhang J; Wang L; Liu C; Luo T; Yan L; Zheng L
Food Chem Toxicol; 2024 Apr; 186():114563. PubMed ID: 38442787
[TBL] [Abstract] [Full Text] [Related]
13. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer.
Lv Q; Zhang Y; Gao W; Wang J; Hu Y; Yang H; Xie Y; Lv Y; Zhang H; Wu D; Hu L; Wang J
Pharmacol Res; 2024 Apr; 202():107126. PubMed ID: 38432446
[TBL] [Abstract] [Full Text] [Related]
14. NETs unleashed: neutrophil extracellular traps boost chemotherapy against colorectal cancer.
Mousset A; Albrengues J
J Clin Invest; 2024 Mar; 134(5):. PubMed ID: 38426501
[TBL] [Abstract] [Full Text] [Related]
15. Pyrvinium Pamoate Induces Cell Apoptosis and Autophagy in colorectal cancer.
Zheng W; Chen K; Lv Y; Lao W; Zhu H
Anticancer Res; 2024 Mar; 44(3):1193-1199. PubMed ID: 38423653
[TBL] [Abstract] [Full Text] [Related]
16. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ
Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734
[TBL] [Abstract] [Full Text] [Related]
17. Diallyl disulfide induces DNA damage and growth inhibition in colorectal cancer cells by promoting POU2F1 ubiquitination.
Xia L; Lin J; Peng M; Jiang X; Peng Q; Cui S; Zhang W; Li S; Wang J; Oyang L; Tan S; Hu Z; Wu N; Tang Y; Luo X; Ren Z; Shi Y; Liao Q; Zhou Y
Int J Biol Sci; 2024; 20(4):1125-1141. PubMed ID: 38385081
[TBL] [Abstract] [Full Text] [Related]
18. Villosol reverses 5-FU resistance in colorectal cancer by inhibiting the CDKN2A gene regulated TP53-pi3k/Akt signaling axis.
Chen H; Deng J; Hou TW; Shan YQ
J Ethnopharmacol; 2024 May; 325():117907. PubMed ID: 38342156
[TBL] [Abstract] [Full Text] [Related]
19. Integrating cfDNA liquid biopsy and organoid-based drug screening reveals pi3k signaling as a promising therapeutic target in colorectal cancer.
Yang H; Xiao X; Zeng L; Zeng H; Zheng Y; Wang J; Li G; Dai W; He Y; Wang S; Peng J; Chen W
J Transl Med; 2024 Feb; 22(1):132. PubMed ID: 38310289
[TBL] [Abstract] [Full Text] [Related]
20. Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic colorectal cancer (PanaMa Phase II Trial, AIO KRK 0212).
Stahler A; Kind AJ; Sers C; Mamlouk S; Müller L; Karthaus M; Fruehauf S; Graeven U; Fischer von Weikersthal L; Sommerhäuser G; Kasper S; Hoppe B; Kurreck A; Held S; Heinemann V; Horst D; Jarosch A; Stintzing S; Trarbach T; Modest DP
Clin Cancer Res; 2024 Apr; 30(7):1256-1263. PubMed ID: 38289994
[TBL] [Abstract] [Full Text] [Related]
[Next]
